|Laropiprant||Prostaglandin receptor antagonist|
|Trade names||Cordaptive, Tredaptive|
|AHFS/Drugs.com||UK Drug Information|
|ATC code||C10AD52 (WHO)|
|(what is this?)|
|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||435.90 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Laropiprant (INN) was a drug used in combination with niacin to reduce blood cholesterol (LDL and VLDL) that is no longer sold, due to increases in side-effects with no cardiovascular benefit. Laropiprant itself has no cholesterol lowering effect, but it reduces facial flushes induced by niacin.
Mechanism of action
Niacin in cholesterol lowering doses (500–2000 mg per day) causes facial flushes by stimulating biosynthesis of prostaglandin D2 (PGD2), especially in the skin. PGD2 dilates the blood vessels via activation of prostaglandin D2 receptors (DP1), increasing blood flow and thus leading to flushes. Laropiprant acts as a selective DP1 antagonist, reducing the vasodilation.
Taking 325 mg of aspirin 20–30 minutes prior to taking niacin has also been proven to prevent flushing in 90% of patients, presumably by suppressing prostaglandin synthesis, but this medication also increases the risk of gastrointestinal bleeding, though the increased risk is less than 1 percent.
In the mid-2000s, in a trial with 1613 patients, 10.2% patients stopped taking the medication in the combination drug group versus 22.2% under niacin monotherapy.
On January 11, 2013, Merck & Co Inc. announced they were withdrawing the drug worldwide as a result of European regulators recommendations.
The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) involved more than 25,000 adults. The treatment group received 2 g of extended-release niacin and 40 mg of laropiprant daily. Study results, reported in July 2014, showed that the combination of niacin and laropiprant did not have any beneficial effects when compared with a placebo treatment and had an increase in adverse effects. 
- "Tredaptive Prescribing Information" (PDF). Merck & Co. Retrieved 2009-11-14.
- Sood, A.; Arora, R. (2009). "Mechanisms of Flushing Due to Niacin and Abolition of These Effects". The Journal of Clinical Hypertension. 11 (11): 685–9. doi:10.1111/j.1559-4572.2008.00050.x. PMID 19878384.
- Richard A. Kunin (1976). "The Action of Aspirin in Preventing the Niacin Flush and its Relevance to the Antischizophrenic Action of Megadose Niacin" (PDF). Orthomolecular Psychiatry. 5 (2): 89–100. Retrieved 2009-11-14.
- Sørensen HT, Mellemkjaer L, Blot WJ, et al. (September 2000). "Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin". Am. J. Gastroenterol. 95 (9): 2218–24. doi:10.1111/j.1572-0241.2000.02248.x. PMID 11007221.
- "For Healthy People Daily Aspirin May Do More Harm Than Good". Medical News Today. 31 August 2009.
- Lai E, De Lepeleire I, Crumley TM, et al. (June 2007). "Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1". Clin. Pharmacol. Ther. 81 (6): 849–57. doi:10.1038/sj.clpt.6100180. PMID 17392721.
- Carey, John (April 29, 2008). "FDA Rejects Merck's Cordaptive". BusinessWeek. Retrieved 2009-11-13.
- "Tredaptive European Public Assessment Report" (PDF). European Medicines Agency. Retrieved November 13, 2009.
- "Merck withdraws cholesterol drug Tredaptive globally". Reuters. January 11, 2013. Retrieved 11 January 2013.
- The HPS2-THRIVE Collaborative Group (July 17, 2014). "Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients". New England Journal of Medicine. 371: 203–212. doi:10.1056/NEJMoa1300955. Retrieved 2014-10-27.